Americord is committed to supporting research into new medical therapies that use stem cells from cord blood and assisting parents whose children need their stem cells to participate in a clinical trial. The company reimburses the full cost of cord blood banking to any of its clients who enroll their babies in clinical trials that require the use of their stem cells. "By donating the cost of cord blood at such a critical moment, we hope to ease the burden that parents face and contribute to the efforts of the stem cell research community," said Martin Smithmyer, the CEO of Americord.
Americord is a leader in the advancement of umbilical cord blood, cord tissue and placenta tissue banking. Americord collects, processes, and stores newborn stem cells from umbilical cord blood for future medical or therapeutic use, including the treatment of more than 80 blood diseases such as sickle cell anemia and leukemia. Founded in 2008, Americord is registered with the FDA and operates in all 50 states. The company's laboratory is CLIA Certified, accredited by the AABB and complies with all federal and state guidelines and applicable licenses. Americord is headquartered in New York, NY. You may visit Americord's website at cordadvantage.com for more information. You may also find Americord on
|SOURCE Americord Registry|
Copyright©2012 PR Newswire.
All rights reserved